Literature DB >> 26712224

Emerging Options After Progression During Crizotinib Therapy.

Solange Peters1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26712224     DOI： 10.1200/JCO.2015.65.1406

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

Review 1.  Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.

Authors:  M Drizou; E A Kotteas; N Syrigos
Journal:  Clin Transl Oncol       Date:  2017-01-04       Impact factor: 3.405

2.  Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis.

Authors:  Anand A Dalal; Annie Guerin; Alex Mutebi; Kenneth W Culver
Journal:  J Drug Assess       Date:  2018-03-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.